Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447
- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants
- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients
- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end
Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the Phase 1 study of AGMB-447 in IPF patients. AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company’s Special and Extraordinary General Shareholders’ Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as nonexecutive members of the Company’s Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants.
Agomab to Participate in Upcoming Investor Conferences
Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences:
- Citi’s 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.
- 2026 Cantor Global Healthcare Conference. Fireside chat on Friday, September 11, 2026 at 8:00 AM ET in New York, NY.
- H.C. Wainwright 28th Annual Global Investment Conference. Fireside chat on Tuesday, September 15, 2026 at 2:00 PM ET in New York, NY.
- Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Wednesday, September 16, 2026 at 9:15 AM ET in New York, NY.
“Our goal is to improve the lives of patients with fibrotic diseases. We are aiming to build a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
Tim Knotnerus, Chief Executive Officer
